DNER and hematologic disorder: Additional efforts have been made to identify multivalent BETi and explore its efficacy in non-NUT carcinoma neoplasms: a recent study demonstrated that a bivalent BET inhibitor AZD5153 (under a phase I clinical trial for refractory/relapsed solid tumor) had better tumor suppression in vivo than other monovalent BET inhibitors [26]; several BET inhibitors have entered clinical trials for patients with solid tumors and hematologic malignancies with variable success in the latter [94,95].